25 August 2017 - NICE reverses stance on Takeda’s Adcetris.

But firm criticises final draft guidance's new restrictions on the non-Hodgkin’s lymphoma drug.

Takeda has claimed a partial win for its non-Hodgkin’s lymphoma drug Adcetris (brentuximab vedotin) after persuading NICE to change its mind and issue new draft guidance.

The firm said its “hard work, flexibility and determination” had successfully overturned previous negative draft guidance from the UK’s cost-effectiveness watchdog.

Read PM Live article